AKEBIA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
AKEBIA THERAPEUTICS, INC. (AKBA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.64 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.71, a 11.25% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.80, a 60.00% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.50.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $1.40, a 60.92% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.87, a 135.14% increase from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.37.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2017 was $5.28, a 269.23% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.64 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $0.71 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $1.40 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $1.42 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $0.98 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $0.80 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $0.87 10-K · filed 2025-03-13 | |||
| 2024-09-30 | $0.51 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $0.51 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $0.50 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $0.37 10-K · filed 2024-03-14 | |||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-28 | |||
| 2017-12-31 | $5.28 10-K · filed 2018-03-12 | |||
| 2016-12-31 | $1.43 10-K · filed 2017-03-06 | |||
| 2015-12-31 | $0.60 10-K · filed 2016-03-14 | |||
| 2014-12-31 | $0.76 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |